Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
Benjamin Levy(Johns Hopkins University), Jonathan W. Riess(University of California Davis Medical Center), Abidemi Adeniji(Boehringer Ingelheim (United States)), J. Madelaine(Université de Caen Normandie), Jaafar Bennouna(Hôpital Foch), Michael Chisamore(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sang‐We Kim(Ulsan College), Hye Ryun Kim(Yonsei University), Mustafa Erman(Hacettepe University Hospital), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), Isabelle Voccia(Boehringer Ingelheim (Canada)), Robert M. Lorence, Olivier Molinier(Centre Hospitalier du Mans), Dolores Isla(Hospital Clínico Universitario Lozano Blesa), Fabrice Barlési(Hôpital Nord), Enriqueta Felip(Institut Català d'Ornitologia), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa)
Cited by 7
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k